Cite
Fcγ-Receptor-Independent Controlled Activation of CD40 Canonical Signaling by Novel Therapeutic Antibodies for Cancer Therapy.
MLA
Beckmann, Karsten, et al. “Fcγ-Receptor-Independent Controlled Activation of CD40 Canonical Signaling by Novel Therapeutic Antibodies for Cancer Therapy.” Antibodies (2073-4468), vol. 13, no. 2, June 2024, p. 31. EBSCOhost, https://doi.org/10.3390/antib13020031.
APA
Beckmann, K., Reitinger, C., Yan, X., Carle, A., Blümle, E., Jurkschat, N., Paulmann, C., Prassl, S., Kazandjian, L. V., Loré, K., Nimmerjahn, F., & Fischer, S. (2024). Fcγ-Receptor-Independent Controlled Activation of CD40 Canonical Signaling by Novel Therapeutic Antibodies for Cancer Therapy. Antibodies (2073-4468), 13(2), 31. https://doi.org/10.3390/antib13020031
Chicago
Beckmann, Karsten, Carmen Reitinger, Xianglei Yan, Anna Carle, Eva Blümle, Nicole Jurkschat, Claudia Paulmann, et al. 2024. “Fcγ-Receptor-Independent Controlled Activation of CD40 Canonical Signaling by Novel Therapeutic Antibodies for Cancer Therapy.” Antibodies (2073-4468) 13 (2): 31. doi:10.3390/antib13020031.